Accelerant Holdings (NYSE: ARX) announced on August 13, 2026, a merger agreement providing for its acquisition by affiliates of Thoma Bravo. Class A and Class B holders are to receive $20.25 per share in cash, without interest, in a transaction carrying more than $4Bn of enterprise value by the company’s description. That is a premium of approximately 49% to the August 12 close of $13.61, and closing is expected in the first half of 2027.

The premium is probably not the most informative figure. Accelerant listed on the NYSE at $21.00 per share in an upsized IPO in July 2025, which places the take-out approximately 3.6% below its listing price thirteen months earlier. The 52-week range of $9.18 to $30.48 shows how much the chosen reference point matters. A large premium to a depressed price is not the same as a premium to intrinsic value, and that gap is where sponsors appear to be finding returns.

Transaction Overview

The transaction is a one-step merger rather than a tender offer. Cherry Tree Merger Sub is to merge into Accelerant, which would survive as a wholly owned subsidiary of Cherry Tree BidCo, an affiliate of Thoma Bravo Discover Fund V, L.P., and the shares are to be delisted and deregistered. Closing requires approval by at least two-thirds of votes cast, HSR expiration or termination, specified foreign antitrust and foreign investment clearances and specified insurance regulatory approvals.

Financing risk appears limited. Discover Fund V has provided an equity commitment letter covering the merger consideration, the estimated ticking amount and refinancing of existing debt, and there is no financing condition. A ticking fee of $0.00333 per share per calendar day, described by the company as 6% per annum, would accrue on top of the $20.25 if insurance approvals delay closing past the Ticking Amount Start Date. That prices the regulatory calendar in advance, and it suggests both sides expected those approvals to take time.

The outside date is August 13, 2027, extendable to November 13, 2027 if only regulatory conditions remain. An active go-shop runs until one minute prior to 12:00 a.m. ET on September 22, 2026, but it is unusually narrow: solicitation is limited to Excluded Parties, counterparties that signed an acceptable confidentiality agreement within six months before signing. A superior proposal therefore remains possible, though within a defined field. Break fees are $56.9MM for a superior proposal with an Excluded Person and $136.5MM otherwise, against a $295.8MM reverse termination fee.

A special committee of independent and disinterested directors ran the process, and both it and the full board unanimously approved the transaction. Entities affiliated with Altamont Capital Partners, holding approximately 82% of voting rights, signed a Voting and Support Agreement on August 13, which likely makes the vote procedural. Altamont and the founders are described as intending to retain equity alongside Thoma Bravo, although the filings state that no binding rollover commitment exists yet.

Strategic Rationale

Thoma Bravo describes itself as the world’s largest software-focused investment firm, with more than $172Bn of assets under management at March 31, 2026. Jeff Radke, Chairman and CEO, framed the rationale in terms of investment capacity: “Accelerant has been building the preeminent specialty insurance marketplace since our founding in 2018… Returning to private ownership with Thoma Bravo’s technology and software expertise, coupled with its vast financial and strategic resources, will enable us to make investments that further position our unique, data fueled platform to be the rails on which specialty insurance runs.”

The choice of fund is also notable. The equity comes from Discover Fund V, the firm’s middle-market strategy rather than its flagship vehicle, which suggests the buyer views Accelerant as a growth-oriented software investment rather than a large-cap platform acquisition. Accelerant also reported second quarter results that day, then withdrew guidance and cancelled its earnings call, so shareholders are assessing a fixed price without a forward view.

The Exchange Model and Competitive Positioning

Accelerant, founded in 2018, is Cayman incorporated and headquartered in Atlanta. It operates the Accelerant Risk Exchange, a data-driven marketplace matching specialty underwriters, largely managing general agents called Members, with Risk Capital Partners. It monetizes mainly through fees on Exchange Written Premium shared with those partners rather than by carrying risk alone, although it retains some. The platform spans 22 countries and approximately 700 specialty products, a footprint that would probably be slow to replicate.

Second quarter Exchange Written Premium was $1,322.3MM, up 23% against 42% growth a year earlier, and the trailing twelve-month figure reached $4.59Bn. Total revenues were $356.9MM versus $219.1MM, net income was $80.0MM, and adjusted EBITDA was $93.1MM at a 30.6% margin against 29.0%. Members numbered 314 against 248, net revenue retention fell to 111% from 151%, and third-party direct written premium rose to 47% of Exchange Written Premium from 27%.

That mix probably explains the sponsor’s interest at this price. Margins expanded, and absolute growth remained strong, yet slower premium growth and lower retention are signals public markets penalize more heavily than private owners do. A private owner may absorb that trade more comfortably in exchange for longer-term positioning.

Broader Implications for Insurance M&A

PwC’s U.S. Insurance Deals 2026 Midyear Outlook reported approximately $29.6Bn of deal value across 191 disclosed transactions in the six months ended May 31, 2026, against $31.8Bn across 207 deals in the prior six months. Approximately 97% of that value came from megadeals. Specialty property and casualty carriers, MGAs and excess and surplus lines businesses continue to drive deal flow, with multi-program MGAs expected to command mid- to high-teens multiples.

Private equity behavior points the same way. PwC’s U.S. Private Equity 2026 Midyear Outlook noted first-half 2026 volume down 34% year over year while aggregate value rose approximately 10%, with average deal size up nearly fourfold. Capital appears to be concentrating in fewer and larger transactions, and Accelerant fits that pattern.

Conclusion

Committed equity, no financing condition, a sponsor guarantee, a supportive holder of approximately 82% of voting rights and a ticking fee for delay together suggest a high probability of completion. Insurance approvals will likely set the timetable. The go-shop does not close until September 22, 2026, so the outcome should not be treated as settled, even though the narrow Excluded Parties definition limits the practical field.

The price itself raises the harder question. A premium of approximately 49% is substantial against a $13.61 close, yet $20.25 remains approximately 3.6% below the $21.00 IPO price of thirteen months ago. Neither figure is dispositive on its own. The transaction most likely shows that the gap between public-market pricing and private assessments of long-term value has widened enough for sponsors to act on it, and boards of recently listed companies may expect similar approaches.

About DelMorgan & Co. (www.delmorganco.com)

With over $300 billion of successful transactions in over 80 countries, DelMorgan’s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.

Learn more about DelMorgan’s Capabilities, Transactions, and why DelMorgan is ranked as the #1 Investment Bank in Los Angeles and #2 in California by Axial.